{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:04:43Z","timestamp":1777863883724,"version":"3.51.4"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma, exhibits genetic heterogeneity and variable treatment responses. Discovering new therapeutic targets is critical to improve outcomes. Given the lack of plasma protein studies for DLBCL, this study aims to first identify novel therapeutic targets based on plasma multi-omics and genome-wide association studies with further verifications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      By two-step training (N = 456,948 participants) and validation (N = 288,927 participants), druggable genes and proteins were identified through the mendelian randomization analyses of expression quantitative trait loci (eQTL) and protein quantitative trait loci (pQTL) using the largest DLBCL dataset of genome-wide association studies. Further verifications were conducted through colocalization analysis, risk factor and related disease analysis, single-cell analysis,\n                      <jats:italic>ex-vivo<\/jats:italic>\n                      experiments and transcriptomics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 16 genes, 2 cis- and 3 trans-regulated plasma proteins were found to be potential targets for DLBCL with significant risks. The colocalization analysis revealed that six genes (APOM, C4A, C4B, CYP21A2, HCP5 and NEU1) and two proteins (MICB and IL17F) shared the causal genetic variants with DLBCL, suggesting their potential as therapeutic targets. The single-cell analysis for DLBCL tumors confirmed their cell type-specific expressions, suggesting that TUBB, with high risk for DLBCL, was highly expressed in malignant B cells with expression levels increasing as the tumor malignancy worsens. Further experiments and transcriptomics using the TUBB inhibitor demonstrated its anti-DLBCL efficacy, highlighting the therapeutic promise of targeting TUBB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study unravels a series of novel therapeutic targets that provide new insights into the development of DLBCL treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1833739","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:32:53Z","timestamp":1777527173000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Unraveling novel therapeutic targets for diffuse large B-cell lymphoma: a plasma multi-omics study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xu","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Hematology, Institute of Hematology, Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Kang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Yang","sequence":"additional","affiliation":[{"name":"West China School of Medicine, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laduona","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Liu","sequence":"additional","affiliation":[{"name":"West China School of Medicine, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanqing","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.ymthe.2024.05.039","article-title":"Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies","volume":"32","author":"Al Hadidi","year":"2024","journal-title":"Mol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.3390\/diagnostics12092067","article-title":"Bioinformatics identification of TUBB as potential prognostic biomarker for worse prognosis in ER\u03b1-positive and better prognosis in ER\u03b1-negative breast cancer","volume":"12","author":"Alhammad","year":"2022","journal-title":"Diagn. (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-019-0752-3","article-title":"Novel and emerging therapies for B cell lymphoma","volume":"12","author":"Ayyappan","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40364-024-00610-z","article-title":"Harnessing natural killer cells for refractory\/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective","volume":"12","author":"Bakhtiyaridovvombaygi","year":"2024","journal-title":"Biomark. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1002\/imt2.107","article-title":"Ultrafast one-pass FASTQ data preprocessing, quality control, and deduplication using fastp","volume":"2","author":"Chen","year":"2023","journal-title":"Imeta"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.12688\/f1000research.8987.2","article-title":"From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline","volume":"5","author":"Chen","year":"2016","journal-title":"F1000Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/circulationaha.119.040180","article-title":"Novel drug targets for ischemic stroke identified through Mendelian randomization analysis of the blood proteome","volume":"140","author":"Chong","year":"2019","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ygyno.2020.11.016","article-title":"Genetically predicted circulating protein biomarkers and ovarian cancer risk","volume":"160","author":"Considine","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians","volume":"362","author":"Davies","year":"2018","journal-title":"Bmj"},{"key":"B11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-021-00208-3","article-title":"Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review","volume":"10","author":"Decruyenaere","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13059-015-0844-5","article-title":"MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data","volume":"16","author":"Finak","year":"2015","journal-title":"Genome Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"eaag1166","DOI":"10.1126\/scitranslmed.aag1166","article-title":"The druggable genome and support for target identification and validation in drug development","volume":"9","author":"Finan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-024-01575-0","article-title":"Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024","volume":"17","author":"Gong","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41580-021-00399-x","article-title":"Regulation of microtubule dynamics, mechanics and function through the growing tip","volume":"22","author":"Gudimchuk","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41467-021-27850-z","article-title":"A genome-wide association study of serum proteins reveals shared loci with common diseases","volume":"13","author":"Gudjonsson","year":"2022","journal-title":"Nat. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s12672-025-03931-z","article-title":"Proteome-wide mendelian randomization identifies FCRL3 and LY9 as potential therapeutic targets for lymphoma","volume":"16","author":"Guo","year":"2025","journal-title":"Discov. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41467-023-44380-y","article-title":"Integrating genetic regulation and single-cell expression with GWAS prioritizes causal genes and cell types for glaucoma","volume":"15","author":"Hamel","year":"2024","journal-title":"Nat. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-Seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinforma."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1038\/s41467-024-49263-4","article-title":"Revealing brain cell-stratified causality through dissecting causal variants according to their cell-type-specific effects on gene expression","volume":"15","author":"Hao","year":"2024","journal-title":"Nat. Commun."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00894-023-05506-7","article-title":"Dynamics of TUBB protein with five majorly occurring natural variants: a risk of cortical dysplasia","volume":"29","author":"Janakiraman","year":"2023","journal-title":"J. Mol. Model"},{"key":"B23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"B25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40164-024-00568-6","article-title":"Vertical targeting of the PI3K\/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma","volume":"13","author":"Kupcova","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41588-023-01561-1","article-title":"Noncoding mutations cause super-enhancer retargeting resulting in protein synthesis dysregulation during B cell lymphoma progression","volume":"55","author":"Leeman-Neill","year":"2023","journal-title":"Nat. Genet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/cm9.0000000000002593","article-title":"Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution","volume":"136","author":"Liang","year":"2023","journal-title":"Chin. Med. J. (Engl)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1093\/brain\/awad070","article-title":"Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis","volume":"146","author":"Lin","year":"2023","journal-title":"Brain"},{"key":"B29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-021-01134-x","article-title":"Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1158\/1078-0432.Ccr-23-1962","article-title":"Sequencing of Anti-CD19 therapies in the management of diffuse large B-Cell lymphoma","volume":"30","author":"Lownik","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-023-00432-z","article-title":"The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma","volume":"12","author":"Lu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-020-01018-6","article-title":"How we treat mature B-cell neoplasms (indolent B-cell lymphomas)","volume":"14","author":"Lumish","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat. Genet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.7150\/jca.115044","article-title":"Identification of plasma protein biomarkers and drug targets for hematologic malignancies by proteome-wide Mendelian randomization","volume":"16","author":"Pan","year":"2025","journal-title":"J. Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nmeth.4402","article-title":"Reversed graph embedding resolves complex single-cell trajectories","volume":"14","author":"Qiu","year":"2017","journal-title":"Nat. Methods"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1038\/s41467-023-39253-3","article-title":"Genome-wide association analysis and Mendelian randomization proteomics identify drug targets for heart failure","volume":"14","author":"Rasooly","year":"2023","journal-title":"Nat. Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41556-020-0532-x","article-title":"Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels","volume":"22","author":"Roider","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s43152-025-00061-0","article-title":"An overview of latest developments in DLBCL its pathogenesis, immune significance, prognosis and targets","volume":"6","author":"Sarode","year":"2025","journal-title":"Curr. Tissue Microenviron. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","article-title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","volume":"9","author":"Schubert","year":"2018","journal-title":"Nat. Commun."},{"key":"B40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12885-022-09380-z","article-title":"Osteoclasts differential-related prognostic biomarker for osteosarcoma based on single cell, bulk cell and gene expression datasets","volume":"22","author":"Shao","year":"2022","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's haematological malignancy research network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41576-020-0268-2","article-title":"Genetics meets proteomics: perspectives for large population-based studies","volume":"22","author":"Suhre","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13073-023-01229-9","article-title":"Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome","volume":"15","author":"Sun","year":"2023","journal-title":"Genome Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1097\/js9.0000000000001514","article-title":"Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials","volume":"110","author":"Sun","year":"2024","journal-title":"Int. J. Surg."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1009440","DOI":"10.1371\/journal.pgen.1009440","article-title":"A more accurate method for colocalisation analysis allowing for multiple causal variants","volume":"17","author":"Wallace","year":"2021","journal-title":"PLoS Genet."},{"key":"B48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/cm9.0000000000001294","article-title":"R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms","volume":"134","author":"Wang","year":"2020","journal-title":"Chin. Med. J. (Engl)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","article-title":"New agents and regimens for diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41588-020-00773-z","article-title":"Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis","volume":"53","author":"Wingo","year":"2021","journal-title":"Nat. Genet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","article-title":"clusterProfiler 4.0: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innov. (Camb)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1007\/s12672-025-03688-5","article-title":"Deciphering the causal relationships between plasma metabolites, peripheral cells, inflammatory factors and DLBCL for discovering novel therapeutic targets","volume":"16","author":"Xu","year":"2025","journal-title":"Discov. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1182\/blood.2020006784","article-title":"Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomark. Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-024-01646-2","article-title":"Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRP\u03b1, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1\/2 study","volume":"17","author":"Yang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/cm9.0000000000002549","article-title":"Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies","volume":"136","author":"Yang","year":"2023","journal-title":"Chin. Med. J. Engl."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e1003897","DOI":"10.1371\/journal.pmed.1003897","article-title":"Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: a mendelian randomization analysis","volume":"19","author":"Yarmolinsky","year":"2022","journal-title":"PLoS Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40364-021-00309-5","article-title":"Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"9","author":"Yin","year":"2021","journal-title":"Biomark. Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","article-title":"Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41588-020-0682-6","article-title":"Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases","volume":"52","author":"Zheng","year":"2020","journal-title":"Nat. Genet."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1365655","DOI":"10.3389\/fmolb.2024.1365655","article-title":"TUBB, a robust biomarker with satisfying abilities in diagnosis, prognosis, and immune regulation via a comprehensive pan-cancer analysis","volume":"11","author":"Zhu","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1097\/cm9.0000000000002940","article-title":"Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large B-cell lymphoma with clinically or biologically high-risk features","volume":"137","author":"Zou","year":"2024","journal-title":"Chin. Med. J. (Engl)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1833739\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:32:55Z","timestamp":1777527175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1833739\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":62,"alternative-id":["10.3389\/fphar.2026.1833739"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1833739","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"1833739"}}